Australian researchers and patients were critical to trialling this breakthrough new treatment for advanced melanoma patients.
Melanoma March 2022 is aiming to raise $1 million for a world-first clinical trial of a Personalised Immunotherapy Platform which could transform melanoma treatment.
A landmark report provides status of melanoma in Australia, and the the roadmap to achieve zero deaths from melanoma this decade.
MIA has joined Sydney Health Partners, with a shared focus on more rapidly translating research evidence into patient benefit.
Cited an incredible 427 times around the world, showing its vital role in improving outcomes for people with advanced melanoma.
The 'Outstanding Research Award' recognises their life-saving discoveries transforming melanoma patient care.
The award recognises her pioneering work in immunotherapy in melanoma, transforming the care of patients worldwide.
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.
Drug therapy looks set to become the standard treatment for high-risk early stage melanoma patients.
“The future looks bright – I truly believe that we will get to zero deaths from melanoma with the trajectory we’re following.”